Keyphrases
Cost-effectiveness
100%
Ocular Hypertension
100%
Hypertension Management
100%
Treatment Study
100%
Primary Open-angle Glaucoma
83%
Intraocular Pressure
50%
Quality-adjusted Life Years
50%
Annual Risk
50%
Glaucoma
33%
Incremental Cost-effectiveness Ratio
33%
Disease Progression
16%
Treatment Delay
16%
Disease Risk
16%
Blindness
16%
Medical Treatment
16%
Treatment Efficacy
16%
Treatment Threshold
16%
Markov Model
16%
Design Cost
16%
Cost-utility Analysis
16%
Cost-effectiveness Threshold
16%
Net Health Benefit
16%
Utility Loss
16%
Nursing and Health Professions
Cost Effectiveness Analysis
100%
Intraocular Hypertension
100%
Open Angle Glaucoma
83%
Intraocular Pressure
50%
Quality Adjusted Life Year
50%
Combination Therapy
33%
Glaucoma
33%
Incremental Cost-Effectiveness Ratio
33%
Disease Exacerbation
16%
Cost Utility Analysis
16%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Ocular Hypertension
100%
Open Angle Glaucoma
83%
Health Care Cost
50%
Intraocular Pressure
50%
Quality Adjusted Life Year
50%
Glaucoma
33%
Combination Therapy
33%
Disease Exacerbation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Intraocular Hypertension
100%
Open Angle Glaucoma
83%
Combination Therapy
33%
Glaucoma
33%
Disease Exacerbation
16%